ArticleUrologie (Heidelberg, Germany)2026
[Prophylaxis of recurrent urinary tract infections by nitroxoline-real-world data of the ProNitrox study].
Article in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance.Biochemical Society transactions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor recurrent urinary tract infections (rUTI), nitroxoline, a hydroxyquinoline derivative with low resistance rates, can be used for long-term prophylaxis (LP). There is little data available on this so far. The clinical routine of LP with nitroxoline was to be assessed in a retrospective, noninterventional study under real-world conditions. In addition to demographic data, the extent of multimorbidity, existing risk factors for rUTI, the type of antibiotic therapy of the last acute episode of rUTI, and the rate of breakthrough infections were of particular interest. MATERIALS AND
methodsIn the period April-October 2024, data from 360 patients who received reinfection prophylaxis with nitroxoline for rUTI from 70 doctors were collected.
resultsThe rate of breakthrough infections was 13% and was predominantly determined from urine culture. Of the documented patients, 20% (women) and 47% (men) were classified as multimorbid and 32% (women) and 48% (men) were classified as geriatric. Furthermore, 31.6% of patients had complicating factors for rUTI. The duration of therapy with nitroxoline was usually 3-6 months, in rare cases more than 2 years.
conclusionThe high number of comorbidities, older age, the high proportion of complicating factors such as urinary tract abnormalities and the use of antibiotics in the last acute episode, which are not intended for LP of rUTI, characterize the present patient group as difficult. Nevertheless, there is a favorable recurrence rate of 13%. The most frequently cited reasons for choosing nitroxoline for LP were good tolerability and effectiveness, the level of resistance and the therapist's positive experiences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.